JP2013508417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508417A5 JP2013508417A5 JP2012535441A JP2012535441A JP2013508417A5 JP 2013508417 A5 JP2013508417 A5 JP 2013508417A5 JP 2012535441 A JP2012535441 A JP 2012535441A JP 2012535441 A JP2012535441 A JP 2012535441A JP 2013508417 A5 JP2013508417 A5 JP 2013508417A5
- Authority
- JP
- Japan
- Prior art keywords
- carbons
- composition
- alkyl
- compound
- group containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 22
- 150000002366 halogen compounds Chemical class 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 102000001307 androgen receptors Human genes 0.000 claims 5
- 108010080146 androgen receptors Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 125000005011 alkyl ether group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- -1 Wherein R 5 Chemical compound 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 0 *[n]1c2ccccc2c2ccccc12 Chemical compound *[n]1c2ccccc2c2ccccc12 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 5
- DRELUPFLXXDYEO-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1C(Nc(cc1)ccc1NC(c(cc1)cc2c1OCCO2)=O)=O Chemical compound CC(C)(C)c(cc1)ccc1C(Nc(cc1)ccc1NC(c(cc1)cc2c1OCCO2)=O)=O DRELUPFLXXDYEO-UHFFFAOYSA-N 0.000 description 1
- JSICPNDQWXVALY-UHFFFAOYSA-N CCC[n]1c(ccc(C(C)=O)c2)c2c2ccccc12 Chemical compound CCC[n]1c(ccc(C(C)=O)c2)c2c2ccccc12 JSICPNDQWXVALY-UHFFFAOYSA-N 0.000 description 1
- AYTGARGOCPEHGL-UHFFFAOYSA-N Cc(cc1)cc2c1OCCO2 Chemical compound Cc(cc1)cc2c1OCCO2 AYTGARGOCPEHGL-UHFFFAOYSA-N 0.000 description 1
- VFCSCFYJARCXSF-UHFFFAOYSA-N Clc1c(C(N2)Nc3cccc4cccc2c34)cccc1 Chemical compound Clc1c(C(N2)Nc3cccc4cccc2c34)cccc1 VFCSCFYJARCXSF-UHFFFAOYSA-N 0.000 description 1
- BHQRPHQIVPXTCQ-XFFZJAGNSA-N O=C1N=C(Nc(cccc2Cl)c2Cl)S/C1=C\c1ccc[o]1 Chemical compound O=C1N=C(Nc(cccc2Cl)c2Cl)S/C1=C\c1ccc[o]1 BHQRPHQIVPXTCQ-XFFZJAGNSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25439509P | 2009-10-23 | 2009-10-23 | |
| US61/254,395 | 2009-10-23 | ||
| PCT/US2010/053916 WO2011050353A1 (en) | 2009-10-23 | 2010-10-25 | Method for treating androgen receptor positive cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013508417A JP2013508417A (ja) | 2013-03-07 |
| JP2013508417A5 true JP2013508417A5 (enExample) | 2013-12-05 |
Family
ID=43900720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012535441A Pending JP2013508417A (ja) | 2009-10-23 | 2010-10-25 | アンドロゲン受容体陽性癌を処置する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8835447B2 (enExample) |
| EP (1) | EP2490531A4 (enExample) |
| JP (1) | JP2013508417A (enExample) |
| KR (1) | KR20120095402A (enExample) |
| CN (1) | CN102573472A (enExample) |
| AP (1) | AP2012006277A0 (enExample) |
| AU (1) | AU2010310477A1 (enExample) |
| BR (1) | BR112012009262A2 (enExample) |
| CA (1) | CA2779309A1 (enExample) |
| EA (1) | EA201290208A1 (enExample) |
| GE (1) | GEP20146138B (enExample) |
| IL (1) | IL219331A0 (enExample) |
| MX (1) | MX2012004624A (enExample) |
| WO (1) | WO2011050353A1 (enExample) |
| ZA (1) | ZA201202557B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012030298A2 (pt) | 2010-05-28 | 2015-09-29 | Univ Texas | compostos de oligo-banzamida e seu uso |
| WO2013023300A1 (en) * | 2011-08-15 | 2013-02-21 | The University Of British Columbia | Inhibitors of androgen receptor activation function-2 (af2) as therapeutics and methods for their use |
| WO2013055793A1 (en) | 2011-10-12 | 2013-04-18 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
| WO2013078288A1 (en) * | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Oligo-benzamide compounds for use in treating cancers |
| WO2013078277A1 (en) | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Oligo-benzamide compounds and their use in treating cancers |
| WO2013178821A1 (en) | 2012-06-01 | 2013-12-05 | Leibniz-Institut für Altersforschung - Fritz-Lipmann-Institut e.V. (FLI) | Inhibitors of the notch signalling pathway and secretion for use in medicine |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| MX375256B (es) * | 2012-07-13 | 2025-03-06 | Gtx Inc | Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms). |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| NZ740700A (en) * | 2012-07-27 | 2019-07-26 | Aragon Pharmaceuticals Inc | Methods and compositions for determining resistance to androgen receptor therapy |
| WO2014153043A1 (en) * | 2013-03-14 | 2014-09-25 | Health Research, Inc. | Compounds and methods for treating cancers |
| US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| CA2924527C (en) * | 2013-09-20 | 2022-07-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compounds for treating prostate cancer |
| US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| US11478453B2 (en) | 2016-07-21 | 2022-10-25 | Hadasit Medical Research Services And Development Ltd. | Treatment for glioblastoma |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224326A (en) | 1978-09-21 | 1980-09-23 | Eli Lilly And Company | Immunosuppressive agents |
| AU626881B2 (en) | 1988-07-14 | 1992-08-13 | F. Hoffmann-La Roche Ag | Benzofused heterocyclics used as pharmaceuticals |
| WO1996014090A1 (en) | 1994-11-07 | 1996-05-17 | Janssen Pharmaceutica N.V. | Compositions comprising carbazoles and cyclodextrins |
| WO2005090282A1 (en) | 2004-03-12 | 2005-09-29 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| CA2562399A1 (en) * | 2004-04-08 | 2005-10-20 | Topotarget A/S | Diphenyl - indol-2-on compounds and their use in the treatment of cancer |
| WO2006002082A2 (en) | 2004-06-16 | 2006-01-05 | Jack Arbiser | Carbazole formulations for the treatment of psoriasis and angiogenesis |
| GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| US20090023742A1 (en) | 2006-03-02 | 2009-01-22 | Dashyant Dhanak | Thiazolones for use as pi3 kinase inhibitors |
| WO2008051523A2 (en) | 2006-10-23 | 2008-05-02 | Georgetown University | Carbazole derivatives useful as medicaments in cancer therapy |
-
2010
- 2010-10-25 AU AU2010310477A patent/AU2010310477A1/en not_active Abandoned
- 2010-10-25 EA EA201290208A patent/EA201290208A1/ru unknown
- 2010-10-25 BR BR112012009262A patent/BR112012009262A2/pt not_active IP Right Cessation
- 2010-10-25 JP JP2012535441A patent/JP2013508417A/ja active Pending
- 2010-10-25 MX MX2012004624A patent/MX2012004624A/es not_active Application Discontinuation
- 2010-10-25 AP AP2012006277A patent/AP2012006277A0/xx unknown
- 2010-10-25 EP EP10825802.1A patent/EP2490531A4/en not_active Withdrawn
- 2010-10-25 WO PCT/US2010/053916 patent/WO2011050353A1/en not_active Ceased
- 2010-10-25 CA CA2779309A patent/CA2779309A1/en not_active Abandoned
- 2010-10-25 US US13/501,566 patent/US8835447B2/en not_active Expired - Fee Related
- 2010-10-25 CN CN2010800474879A patent/CN102573472A/zh active Pending
- 2010-10-25 GE GEAP201012711A patent/GEP20146138B/en unknown
- 2010-10-25 KR KR1020127013113A patent/KR20120095402A/ko not_active Withdrawn
-
2012
- 2012-04-10 ZA ZA2012/02557A patent/ZA201202557B/en unknown
- 2012-04-22 IL IL219331A patent/IL219331A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508417A5 (enExample) | ||
| JP2012121931A5 (enExample) | ||
| JP2010519270A5 (enExample) | ||
| MY160399A (en) | Compounds, compositions, and methods for preventing metastasis of cancer cells | |
| JP2014530861A5 (enExample) | ||
| CY1118104T1 (el) | Νεα κυτταροστατικα νουκλεοζιδια 7-αποαζαπουρινης | |
| JP2013010749A5 (ja) | カルバゾール化合物 | |
| WO2011111880A9 (ko) | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 | |
| JP2011088902A5 (enExample) | ||
| MA32383B1 (fr) | DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE | |
| SV2011003849A (es) | Derivados de picolinamida como inhibidores de quinasa | |
| JP2013539778A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| JP2013515822A5 (enExample) | ||
| EA201070477A1 (ru) | Транс-кломифен для лечения метаболического синдрома | |
| JP2012144574A5 (enExample) | ||
| EA201290208A1 (ru) | Способ лечения андроген-рецептор позитивных раковых заболеваний | |
| JP2011006405A5 (ja) | 化合物 | |
| JP2012140436A5 (ja) | 物質 | |
| SG10201810928SA (en) | Novel antitumoral use of cabazitaxel | |
| NZ718514A (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
| JP2011500690A5 (enExample) | ||
| JP2015514327A5 (enExample) | ||
| WO2007124345A3 (en) | Beta-amyloid pet imaging agents | |
| JP2012054542A5 (ja) | トリアゾール誘導体および複素環化合物 |